Showing 1 - 10 of 20
Digesting Trump's trip through Asia
Oped, Thitinan Pongsudhirak, Published on 07/11/2025
» Storming through Asia last week, US President Donald Trump's first stop in Kuala Lumpur on Oct 26, before moving on to Japan and South Korea over the next four days, capped by his meeting with Chinese President Xi Jinping before returning to Washington, was the most consequential for Southeast Asian economies.
Aid as leverage
Oped, Postbag, Published on 17/10/2025
» Re: "Solving the conflict in Myanmar", (Opinion, Sept 15). The humanitarian crisis in Myanmar presents a complex and deeply troubling challenge for the international community.
A Faustian bargain for the Global South
Oped, Jayati Ghosh, Published on 05/08/2025
» US President Donald Trump's tariff policies have unleashed global economic turmoil and a wave of protectionist measures. While many of his frequently changing tariffs may prove short-lived, their use as geopolitical weapons is poised to reshape international trade for years to come.
Will Indonesia regret its trade deal with Trump?
Oped, Lili Yan Ing, Published on 23/07/2025
» Be careful what you wish for, lest it come true. That ancient proverb comes to mind when considering the eagerness of America's trade partners around the world to negotiate deals with US President Donald Trump's administration. Four countries already have, with Indonesia the latest to do so -- and possibly the first to regret it.
Is Israel spared?
Oped, Postbag, Published on 14/07/2025
» Re: "Trump threatens 35% tariff on Canada", (World, June 12).
Unite to solve neglected diseases
Oped, Muhammad Radzi Abu Hassan, Published on 29/04/2025
» The successful collaboration between the health ministries of Malaysia and Thailand, industry partners in Egypt and Malaysia, and the Drugs for Neglected Diseases initiative (DNDi) to bring a new hepatitis C antiviral drug -- ravidasvir -- to market in 2022 was an important milestone. For years, a 12-week course of treatment using sofosbuvir cost between $70,000 (2.34 million baht) and $80,000, putting it out of reach for many in the Global South. But ravidasvir -- a safe and effective alternative when combined with sofosbuvir -- costs far less, averaging less than $500 per course.
Asean's strategy against US tariffs
Oped, Kavi Chongkittavorn, Published on 22/04/2025
» On April 2, President Donald Trump's so-called "Liberation Day" quickly morphed into "Solidarity Day" for all 10 members of Association of Southeast Asian Nations (Asean).
Global South will pay for trade war
Oped, Jayati Ghosh, Published on 22/04/2025
» US President Donald Trump's sweeping tariffs have unleashed economic chaos, roiling stock and bond markets and triggering panic around the world, especially in lower-income countries that rely heavily on exports to the United States. The result could be an entirely manufactured global recession, with the developing world bearing the brunt.
Beware the false promise of tariffs
Oped, Dambisa Moyo, Published on 19/04/2025
» In this era of growing protectionism, defending globalisation can feel like a losing proposition. But rather than retreat from the debate, it is more urgent than ever to spell out the costs of a trade war, which threatens to accelerate the fragmentation of the global economy because it is really a war on trade itself. To challenge the logic behind the US administration's protectionist agenda effectively, we must first understand it in clear and concrete terms.
Trump's return presents an opportunity for India
Oped, Arvind Subramanian, Published on 10/12/2024
» It might be tempting to assume that Donald Trump's return to the White House augurs stability in US-India relations. After all, there is strong bipartisan support in Washington for deeper ties, particularly as a counterbalance to China's growing economic and geopolitical influence.